Granisetron Baxter (Granisetron)

Granisetron Baxter is indicated for the prevention of nausea and vomiting in specific clinical situations.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV) in patients receiving moderately to highly emetogenic regimens.
• Prevention of postoperative nausea and vomiting (PONV) after surgical procedures requiring anesthesia.
• Use as part of a multimodal antiemetic regimen in oncology protocols.
• Administration prior to the start of chemotherapy or surgery to reduce acute emetic episodes.
• Consideration in patients who have experienced inadequate control with other antiemetics.

The safety profile of Granisetron Baxter includes both frequent and less common adverse events that are generally related to its pharmacologic action.

Common

• Headache (mild to moderate).
• Constipation or changes in bowel habits.
• Diarrhea.
• Fatigue or mild drowsiness.

Serious

• Severe allergic reactions such as anaphylaxis or angioedema.
• Cardiac rhythm disturbances, including QT interval prolongation and associated arrhythmias.

Before using Granisetron Baxter, clinicians should evaluate several precautionary factors to ensure safe administration.

• Known hypersensitivity to granisetron or other 5‑HT3 antagonists.
• History of cardiac conduction abnormalities or prolonged QT interval.
• Presence of electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) that may increase cardiac risk.
• Caution in patients with hepatic impairment, as metabolism may be altered.
• Consider potential effects on fetal development; use only if the anticipated benefit outweighs the risk.
• Monitor for signs of serotonin syndrome when combined with serotonergic agents.

Granisetron Baxter may interact with other medications, influencing its efficacy or safety profile.

Avoid

• Concurrent use with other 5‑HT3 antagonists (duplicate antiemetic effect).
• Co‑administration with drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution

• Serotonergic agents such as SSRIs, SNRIs, or triptans (risk of serotonin syndrome).
• CYP3A4 inhibitors or inducers that could alter granisetron plasma concentrations.
• Medications affecting electrolyte balance, which may increase cardiac risk.